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ABSTRACT 
 
Background: There is emerging evidence of the role of diabetes as a risk factor for 
frailty. However, the mechanisms of this association are uncertain.  
Methods: Prospective cohort study of 1750 non-institutionalized individuals aged ≥60 
years recruited in 2008-2010. At baseline, information was obtained on health 
behaviors, morbidity, cardiometabolic biomarkers, and antidiabetic treatments. 
Individuals were considered diabetic if they reported a physician-diagnosis or had 
fasting serum glucose ≥126 mg/dl. Study participants were followed-up through 2012 to 
assess incident frailty, defined as at least three of the five Fried criteria.  
Results: At baseline, the cohort included 346 individuals with diabetes and 1404 
without it. Over a mean 3.5-year follow-up, 115 cases of incident frailty were 
ascertained. After adjustment for age, sex and education, participants with diabetes 
showed an increased risk of frailty (odds ratio [OR]: 2.18; 95% confidence interval 
[CI]: 1.42-3.37). Additional adjustment for health behaviors and abdominal obesity 
yielded a 29.7% reduction in the OR (OR: 1.83; 95%CI: 1.16-2.90). Subsequent 
adjustment for morbidity produced an additional 8.4% reduction (OR: 1.76; 95%CI: 
1.10-2.82), and for cardiometabolic biomarkers, a further 44% reduction (OR: 1.32; 
95% 0.70-2.49). In particular, adjustment for HbA1c, lipoproteins and triglycerides 
accounted for the greatest reductions. Finally, additional adjustment for oral antidiabetic 
medication reduced the OR to 1.01 (95%CI: 0.46-2.20), while adjustment for nutritional 
therapy increased it to 1.64 (95%CI: 0.77-3.49). 
Conclusions: Diabetes mellitus is associated with higher risk of frailty; this association 
is partly explained by unhealthy behaviors and obesity and, to a greater extent, by poor 
glucose control and altered serum lipid profile among diabetic individuals. Conversely, 
diabetes nutritional therapy reduces the risk of frailty.    
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INTRODUCTION 
 
In 2013, the worldwide prevalence of diabetes mellitus among those aged 60 to 79 years 
was around 19%, accounting for over 35% of all adult cases of diabetes and around 70% 
of the global health expenditure for the disease (1). According to projections from the 
International Diabetes Foundation (IDF), by 2035 the number of patients with diabetes 
will have risen to 590 million (1). The largest increase is projected among the elderly, 
with an expected 252.8 million cases in 2035.  
Diabetes is one of the leading causes of disease burden in old age (2). Diabetic older 
adults are at increased risk of cardiovascular disease and cancer, as well as cognitive 
dysfunction (3), functional limitations and disability (4,5). Frailty, a geriatric syndrome 
characterized by declines in functioning across multiple systems, is also an important 
predictor of disability (6). However, very few studies have evaluated the prospective 
relationship between diabetes and frailty (7-10), and the mechanisms that could explain 
this association are uncertain.  
In this study, we hypothesize that three types of factors could help explain the potential 
association between diabetes and frailty. First, it is well known that diabetes is 
associated with unhealthy lifestyles (e.g., poor diet, sedentary behavior) and severe 
morbidity (e.g., obesity, cardiovascular disease) (1), which in turn may lead to frailty 
(11). Second, certain cardio-metabolic abnormalities frequently found in diabetes (e.g., 
chronic inflammation, hyperglycemia, dyslipidemia or high blood pressure), which are 
mediators of some of its microvascular and macrovascular complications, could also 
exert a role in frailty development. Third, there is evidence that the prognosis of diabetic 
patients can be improved by nutrition and glucose-lowering therapy, as well as by 
appropriate management of cardiovascular risk factors (hypertension and 
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hyperlipidemia) (12), and we hypothesize that these treatments could also reduce the 
risk of frailty among diabetic older adults.  
Accordingly, this study has two objectives. First, we evaluated the prospective 
association between diabetes and the risk of frailty in older adults. Second, we 
examined the degree to which this association could be explained by unhealthy 
behaviors, comorbid conditions and cardio-metabolic biomarkers associated with 
diabetes, as well as the role of antidiabetic treatment and antihypertensive or lipid-
lowering medication. 
PARTICIPANTS AND METHODS 
Study participants and design 
We analyzed data from the Seniors-ENRICA cohort, whose methods have been reported 
elsewhere (13). This cohort was established in 2008-2010 with 2614 non-
institutionalized individuals aged ≥ 60 years. At baseline, computer-assisted telephone 
interviews were used to obtain information on socio-demographic factors, health 
behaviors and morbidity. Additionally, home visits were performed to conduct a 
physical examination, obtain 12-h fasting blood samples and record usual diet and 
prescribed medication. Participants were followed-up until 2012, when a second wave 
of data collection was performed, again including a phone interview, a physical exam, 
and diet and medication assessment at home. Ninety-five participants (3.6%) died 
during follow-up. From the remaining 2519 subjects, 2085 had complete information on 
frailty at the end of follow-up. From these 2085 individuals, we further excluded 174 
who either lacked information on frailty or were frail at baseline, 36 without complete 
data to evaluate their diabetic status and 135 with missing information on other study 
variables, leading to a final sample of 1750 individuals.  
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All study participants gave written informed consent, and the Clinical Research Ethics 
Committee of the ‘La Paz’ University Hospital in Madrid approved the study.  
Study variables 
Frailty 
Frailty was assessed at baseline and at the end of follow-up with a slight modification of 
the phenotypic criteria proposed by Fried et al. in the Cardiovascular Health Study 
(CHS) (14). Individuals meeting ≥3 of the following five criteria were considered as 
frail: 1) Self-reported exhaustion, based on a response of “≥3/4 days a week” to any of 
the following questions from the Center for Epidemiologic Studies Depression Scale : 
“I felt that anything I did was a big effort” or “ I felt that I could not keep on doing 
things”; 2) Weight loss, defined as unintentional loss of ≥4.5 kg of body weight in the 
preceding year; 3) Low physical activity, defined as walking ≤2.5 h/week in men and ≤2 
h/week in women; 4) Weakness, defined as the lowest quintile in the CHS of maximum 
strength in the dominant hand adjusted for sex and body mass index. Strength was 
measured as the highest of two consecutive measures with a Jamar dynamometer; and 
5) Slow walking speed, defined as the worst cohort-specific quintile in the three-meter 
walking speed test, adjusted for sex and height.  
Diabetes mellitus 
Participants were considered diabetic if they reported a physician-diagnosis of diabetes 
or had fasting serum glucose ≥126 mg/dl. Glucose was measured using the oxidase 
glucose technique (ADVIS 2400 Chemistry System analyzer, Siemens). 
Sociodemographic variables, lifestyle, obesity and reported comorbidity 
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At baseline, self-reported information was obtained on age, sex educational level, 
tobacco and alcohol consumption. Physical activity was measured with the 
questionnaire used in the EPIC-Spain cohort (15), and sedentary behavior was estimated 
by time spent watching television as assessed by the Nurse´s Health Study questionnaire 
validated in Spain (16). Food consumption in the previous year was collected using a 
validated computerized diet history developed from that used in the EPIC-Spain cohort 
study, and energy intake was calculated using Spanish food composition tables (17). 
Adherence to the Mediterranean diet was summarized using the Mediterranean Diet 
Adherence Screener (MEDAS) index (18).  
Baseline weight, height and waist circumference (WC) were measured at home. 
Measurements were performed twice using electronic scales (model Seca 841, precision 
to 0.1 kg), portable extendable stadiometers (model Ka We 44 444Seca) and flexible, 
inelastic belt-type tapes, respectively. Mean values of the two measurements were used 
for the analyses. Body Mass Index (BMI) was calculated as weight in kg divided by 
square height in m. Obesity was defined as BMI ≥30 kg/m2, and abdominal obesity as 
WC >102 cm in men and >88 cm in women. 
Participants also reported if they had previously suffered from any of the following 
physician-diagnosed diseases: cardiovascular disease (ischemic heart disease, stroke or 
heart failure), cancer, chronic respiratory disease (chronic bronchitis or asthma), 
osteoarthritis, arthritis or hip fracture.  
Cardio-metabolic biomarkers 
High sensitivity C-reactive protein (hs-CRP) was determined by latex-enhanced 
nephelometry. Fibrinogen was measured by the coagulation method and leptin by 
enzyme-linked immunoassay (DBC, Diagnosis Biochem Canada, Inc). Triglycerides 
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were measured by the glycerol phosphate oxidase method; total cholesterol by 
enzymatic methods using cholesterol esterase and cholesterol oxidase; HDL cholesterol 
by the direct method using elimination/catalase; and LDL cholesterol was estimated 
using the Friedewald formula..Glycemic control was assessed by the level of glycated 
hemoglobin (HbA1c), measured by high-performance liquid chromatography (Adams 
A1c HA-8160, Arkray). 
Blood pressure was measured with standardized procedures using validated automatic 
devices (Omron model M6) and three cuff sizes according to arm circumference. Two 
sets of blood pressure readings were made separated by 90 minutes. In each set, blood 
pressure was measured 3 times at 1-2 minute intervals, after resting 3 to 5 minutes in a 
seated position. Systolic blood pressure was calculated as the mean of ≥3 of the last 5 
readings. 
Management of diabetes and cardiovascular risk factors 
Nutrition therapy was self-reported. Drug treatment for diabetes (including oral 
antidiabetics and insulin), hypertension and hyperlipidemia was checked by the study 
staff against drug packages at home. 
Other variables 
Functional limitations in instrumental activities of daily living (IADL) were assessed 
with the Lawton and Brody Scale. Due to cultural issues, the questions on subjects’ 
ability to prepare meals, do household chores, and care for clothing were excluded in 
men. The presence of limitation in at least one IADL was considered as disability. 
Statistical analysis 
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In a first step, we used logistic regression models to evaluate the association of lifestyle, 
morbidity, cardio-metabolic biomarkers, and management of diabetes and other 
cardiovascular risk factors at baseline, with risk of frailty. These models were adjusted 
for age, sex and educational level. 
We then estimated the association between diabetes at baseline and risk of frailty using 
logistic regression models with progressive levels of adjustment. In the basic model, we 
only considered age, sex and educational level as covariates. We then fitted four models 
by progressively adding subsets of covariates according to the following pattern: 1) 
Lifestyle (smoking, alcohol consumption, time spent watching television, physical 
activity, MEDAS score, energy intake) and anthropometric factors (either abdominal or 
general obesity); 2) Morbidity (cardiovascular disease, chronic respiratory disease, 
cancer, arthritis, osteoarthritis, fracture) ; 3) Cardio-metabolic biomarkers (CRP, 
fibrinogen, leptin, systolic blood pressure, triglycerides, HDL-cholesterol, LDL-
cholesterol, HbA1c); and 4) Management of diabetes and cardiovascular risk factors 
(diabetes, nutritional therapy, oral antidiabetics, insulin, antihypertensive or lipid-
lowering medication). 
Next, we estimated the association between diabetes and onset of each frailty criterion 
among robust adults (free of all five criteria) at baseline. Again, four main models that 
accounted for the previously defined subsets of covariates were fitted.  
Statistical significance was set at two-sided P <0.05. The analyses were performed with 
Stata®, version 13.0. 
RESULTS 
Table 1 shows the socio-demographic, lifestyle, clinical and biochemical variables of 
the study participants, according to diabetic status. Compared to the non-diabetic 
10 
 
individuals, those with diabetes were on average one year older, were more frequently 
men, had lower educational level and showed a higher prevalence of tobacco 
consumption, obesity and sedentary behavior. Also, they were less frequently moderate 
drinkers, showed a higher frequency of cardiovascular disease, a lower level of HDL- 
and LDL-cholesterol and a higher level of triglycerides. Among diabetic participants, 
65% were following nutritional therapy, and 50% were being treated with oral 
antidiabetics and 12% with insulin. 
During a mean 3.5-year follow-up, 115 cases of incident frailty were ascertained. Table 
2 presents the results of logistic regression models examining the relationship between 
the main baseline variables and the risk of frailty. Older participants, women, 
participants with sedentary behavior or obesity, as well as those with osteoarthritis or 
arthritis showed an increased risk of frailty. Conversely, participants with higher 
educational level, moderate drinkers and those with higher adherence to the 
Mediterranean diet, showed a decreased risk of frailty. Regarding the cardio-metabolic 
biomarkers, a positive link with frailty was observed for CRP, leptin, tryglicerides and 
HbA1c, while a negative link was observed for HDL- and LDL-cholesterol.  
During the follow-up, 76 individuals developed frailty among the 1404 non-diabetic 
subjects, and 39 among the 346 subjects with diabetes. Table 3 presents the main results 
of the study. After adjustment for age, sex and educational level, participants with 
diabetes showed an increased risk of frailty (odds ratio [OR]: 2.18; 95% confidence 
interval [CI]: 1.42-3.37; Basic model). Additional inclusion of lifestyle factors and 
central obesity yielded a 29.7% change in the OR (OR: 1.83; 95%CI: 1.16-2.90; Model 
1). This last result was virtually the same when considering general (BMI) instead of 
abdominal obesity. Further adjustment for morbidity at baseline (model 2) produced an 
additional 8.4% reduction in the OR (OR: 1.76; 95%CI: 1.10-2.82), while adjustment 
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for the cardio-metabolic biomarkeres (model 3) yielded an additional 44% reduction in 
the OR (OR: 1.32; 95% 0.70-2.49), which lost significance. In particular, inclusion of 
HbA1c, lipoproteins and triglycerides accounted for the greatest reductions. Finally, 
while further adjustment of model 3 for insulin treatment, antihypertensive or lipid-
lowering medication resulted in a marginal change in the OR, adjustment for oral 
antidiabetics reduced the OR to 1.01, and adjustment for nutritional therapy increased it 
to 1.64.  
To assess the robustness of the results, we conducted several sensitivity analyses. First, 
we replicated the analyses after excluding individuals with limitations in IADL. Second, 
we further adjusted the models for incident morbidity. And third, we repeated the 
analyses using the lowest quintile in our study sample for maximum strength in the 
dominant hand adjusted for sex and BMI. All these analyses yielded similar results to 
those presented in the main tables (data not shown). 
Table 4 shows the effect of diabetes on each component of the frailty syndrome. The 
results suggest that the increased risk of frailty observed in individuals with diabetes is 
mainly driven by a reduction in walking speed and an increased risk of unintentional 
weight loss. Similar to the case for overall frailty, these associations were partly 
explained by the cardio-metabolic biomarkers (specifically higher HbA1c and worse 
lipid profile ) and were modulated by management of diabetes, in particular nutrition 
therapy. Diabetes also showed a non-statistically significant increased risk of muscle 
weakness. However, no association was observed with the risk of exhaustion or low 
physical activity.  
DISCUSSION 
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In this study of community-dwelling older adults in Spain, diabetes was associated with 
an increased risk of frailty over 3.5 years of follow-up. This increased risk was partly 
explained by unhealthy behaviors and obesity and, to a greater extent, by poor glucose 
control and altered serum lipid profile among diabetic individuals. Conversely, 
nutritional therapy modulated the increased risk of frailty observed among subjects with 
diabetes.  
Patients with type-2 diabetes have an increased prevalence of lipid abnormalities, which 
contribute to their higher risk of cardiovascular events. As an example, results from the 
Multiple Risk Factor Intervention Trial, with 5,163 diabetic men and 342,815 non-
diabetic men followed for an average of 12 years, showed that the absolute risk of 
coronary mortality for each 20 mg/dl increase in total cholesterol was 3-5 times higher 
in diabetic than in non-diabetic men (19). Similarly, poor glycemic control is known to 
increase the risk of long-term complications among diabetic individuals (20,21), with 
evidence showing that a 1% point elevation in HbA1c concentrations in persons with 
type 2 diabetes is associated with an approximate 18% increased risk of cardiovascular 
disease (20) and a 15% increased risk of all-cause mortality (20).  Our results suggest 
that poor glycemic and lipid control may also raise the risk of frailty associated with 
diabetes mellitus in older adults.   
High concentrations of glucose might lead to systemic chronic inflammation, which has 
been identified as a risk factor for frailty (22). Some studies have also shown that older 
diabetic individuals have an accelerated loss of skeletal muscle strength (23,24), which 
is more pronounced among those with poor glycemic control (HbA1c>8%) (25). Still, 
to our knowledge only one previous study has evaluated the role of hyperglycemia in 
frailty development. Results from this investigation, based on the Women´s Health and 
Aging Studies I and II, displayed a positive association between HbA1c and prevalent 
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frailty, which was independent of coronary artery disease (26). Additionally, there is 
evidence from the Active Steps for Diabetes program that diabetes education can be 
effective in reducing HbA1c and frailty (27). 
Lower serum total cholesterol levels among older adults are predictive of all-cause 
mortality (28,29) and functional decline (30). In the Three-City cohort study, with 6,141 
participants aged ≥65 years and followed up for 7 years, high triglycerides (≥1.7 
mmol/L) were significantly associated with the incidence of mobility limitations (using 
the Rosow and Breslau scale) and with worse scores in the basic and instrumental 
activities of daily living scales (31). Also, low HDL-cholesterol concentrations (≤1.04 
mmol/L in men and ≤1.29 mmol/L in women) were associated with an increased risk of 
mobility limitations (31). Results from the ilSIRENTE study found that, in older adults 
aged ≥80 years, HDL-cholesterol concentrations were inversely associated with 
physical function (as measured using a 4 meter walking-speed test, and the basic and 
instrumental activities of daily living scales) (32); and in this same study, frail 
individuals with high HDL-cholesterol levels at baseline showed better survival at two 
years (33).    
In our study, receiving nutritional therapy decreased the diabetes-related risk of frailty. 
Evidence from randomized controlled trials shows that diabetes nutrition therapy is 
effective to improve blood glucose control (34). Recent trials have also indicated that 
evidence-based nutritional care is beneficial in reducing total triglycerides, cholesterol 
(35) and LDL levels (35) and increasing HDL-cholesterol (36). Often the initiation of 
nutritional therapy is accompanied by other lifestyle changes that can modulate the risk 
of frailty, including regular exercise or smoking cessation. Moreover, nutritional 
therapy can also produce weight loss, which has been shown to improve physical 
function among older adults, independently of changes in physical activity (37).  
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In our study, treatment with oral antidiabetics seemed to aggravate the risk of frailty 
observed among diabetic subjects, an unexpected finding that was independent of 
glycemic control. Unfortunately, we were unable to evaluate the role of specific oral 
glucose-lowering agents on the association between diabetes and frailty.  It has been 
hypothesized that the use of certain antidiabetic drugs (e.g, glibenclamide) could 
contribute to the age-related muscle atrophy and sarcopenia associated with type 2 
diabetes (38), and there is also evidence that some oral antidiabetics (e.g, metformin or 
disaccharidase inhibitors) tend to promote weight loss (37). On the other hand, recent 
evidence from the Study of Osteoporotic Fractures suggested that use of insulin 
sensitizers (metformin and/or thazolidinedione) could attenuate the loss of usual walk 
speed observed in women with diabetes (39). In light of these conflicting data, future 
research should further evaluate the role of specific hypoglycemic agents on muscle 
weakness, functional impairment and risk of frailty. 
Our results suggest that the increased risk of frailty observed among diabetic individuals 
is mainly driven by reductions in walking speed and, to a lesser extent, by an increased 
risk of unintentional weight loss and weakness.  
Lower-limb muscle strength has been shown to be a good predictor of incident mobility 
limitations (40), hospitalization (41) and death (42) in older adults. In this regard, 
previous studies linking diabetes with reduced walking speed (39,43-45) have attributed 
this association to the accelerated loss of skeletal muscle strength that is commonly seen 
in older adults with this metabolic disease (23,24). To address whether diabetes-related 
muscle impairments could mediate the association between diabetes and low walking 
speed, researchers from the InCHIANTI study assessed walking performance and 
lower-extremity muscle mass, strength and power in a sample of 835 older adults (43). 
They found that lower-limb muscle characteristics accounted for 24.3% and 15.1% of 
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walking speed difference comparing diabetic and non-diabetic subjects in a 4- and 400- 
meter walk test, respectively. The Study of Osteoporotic Fractures (39) showed that 
diabetes was prospectively associated with declines in walking speed, but not in hand-
grip strength. This last finding is in accordance with the Health, Aging, and Body 
Composition Study (23), where, although type 2 diabetes was associated with an 
accelerated loss of leg muscle strength and quality, no association with arm muscle 
strength or quality was observed. Similarly, although in our study diabetes was 
associated with decreased walking speed, we observed no significant association 
between diabetes and hand-grip weakness. In addition to loss of lower-limb strength, 
the following mechanisms have been proposed as potential contributors to the decline in 
walking speed observed among diabetic individuals: poor sensory and motor peripheral 
nerve function (46), lower cerebral vasoreactivity (47), poor balance(46) and fear of 
falls (48). 
Unintentional weight loss among diabetic individuals may occur due to uncontrolled 
hyperglycemia, use of certain oral anti-diabetics (e.g, sodium glucose transporter 
inhibitors) or coexistence of comorbid conditions (e.g, depression). In older persons, 
uncontrolled weight loss is often accompanied by decreases in muscle and bone mass, 
which can accelerate functional declines (49,50) and in turn may increase the risk of 
frailty.  In this sense, as occurs in the elderly from the general population (51), 
unintentional weight loss among diabetic adults has shown to be an important predictor 
of mortality (52). 
Among the patients with diabetes in our study, the levels of HbA1c were quite low. In a 
previous work comparing the achievement of individualized glycemic target between 
Spain and the US, we found that Spanish diabetic patients over 45 years had better 
glucose control than those in the US, particularly among patients free of diabetes 
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complications (53). These findings could be due to differences in comorbidities or in 
time since diagnosis between patients in both countries, and could also result from 
differences in access to health services and a greater overtreatment of glucose levels in 
Spain than in the US (54). Future research should address these differences in detail.   
Strengths of this study include its prospective design and objective assessment of 
diabetes and frailty according to standard criteria. Also, we evaluated an extensive list 
of health behaviors, biomarkers and clinical variables that could contribute to the 
association between diabetes and frailty. Moreover, our results were robust to different 
sensitivity analyses. Among the potential limitations, no information was included 
about type of diabetes, although in elderly people type-2 diabetes is predominant. 
Second, because we lacked information on postprandial serum glucose concentrations, 
we may have missed some patients with diabetes since fasting glucose can be below 
126 mg/dl in the early stages, but have postprandial values above 200 mg/dl. Third, we 
lacked complete information on specific antidiabetic agents. Fourth, information on 
comorbidities was self-reported so it is subject to recall bias. However, in Spain, a 
country with a good access to health services, which are free of charge, self- reporting 
of severe comorbidities is generally valid when compared to clinical records. Fifth, 
when evaluating functional limitations in IADL, exclusion of household chores, meal 
preparation and care of clothing tasks in men may have led to a small underestimation 
of disability in this gender group. Finally, we could not evaluate the contribution of 
lower extremity muscle properties to the observed associations.  
In conclusion, diabetes mellitus is associated with a higher risk of frailty among non-
institutionalized older adults. A number of health behaviors and cardio-metabolic 
biomarkers partly explain this association; moreover, nutritional therapy may reduce the 
risk of frailty associated with diabetes. Future research should evaluate whether diet- 
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and other behavioral interventions can reduce the risk of frailty among diabetic older 
adults. The role of specific antidiabetic agents in frailty should also be further 
investigated. 
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Table 1: Baseline characteristics of participants in the Seniors-ENRICA cohort study by diabetic 
status. N=1750. 
 Diabetes  
 No 
n=1404 
Yes 
n=346 
p-value 
Socio-demographic factors    
Women 53.9 41.0 <0.01 
Age, years 68.4 (6.3) 69.4 (6.4) <0.01 
Educational level    
≤Primary 51.6 58.4  
Secondary 26.5 17.6  
University 21.9 24.0 <0.01 
Health behaviors    
Smoking     
Never 59.9 50.6  
Former 29.5 35.3  
Current 10.6 14.1 <0.01 
Alcohol consumption    
Never 34.6 37.3  
Ex-drinker 7.7 10.1  
Current moderate  drinker*  29.3 24.0  
Current heavy drinker* 28.4 28.6 0.15 
 Time watching TV, (hours/day) 17.2 (10.7) 19.7 (11.2) <0.01 
Physical activity, (MET-hours/week) 22.0 (14.9) 21.5 (16.9) 0.60 
MEDAS  score†  7.2 (1.8) 7.0 (2.0) 0.12 
Energy intake, (kcal/day) 2040.8  (556.5) 2026.0 (614.6) 0.66 
Abdominal obesity  53.1 70.8 <0.01 
Morbidity     
Cardiovascular disease‡ 4.4 8.4 <0.01 
Cancer 1.6 2.3 0.80 
Asthma or chronic bronchitis 6.9 7.8 0.56 
Osteoarthritis/arthritis 47.1 48.6 0.62 
Hip fracture 1.4 0.3 0.08 
Cardio-metabolic biomarkers    
HS-CRP, ng/ml 
 
Model 2 and fibrinogen 
Model 2 and leptin 
Model 2 and systolic blood pressure 
Model 2 and HDL and Triglycerides 
Model 2 and HDL and Triglycerides and LDL 
Model 2 and glycated hemoglobin  
Model 2 and all the above mediators (model 3) 
0.36 (0.7) 0.39 (0.6) 0.38 
Fibrinogen, mg/dl 368 (7.2) 375 (7.4) 0.11 
Leptin, ng/ml 23.2 (19.5) 22.7 (19.2) 0.69 
Systolic blood ressure, mm Hg 138.2 (18.6) 142.4 (19.4) 0.01 
HDL-cholesterol, mg/dl 55.9 (14.1) 48.2 (13.3) <0.01 
Triglycerides, mg/dl 107.6 (47.2) 131.2 (61.3) <0.01 
LDL-cholesterol, mg/dl 131.8 (29.2) 118.2 (30.2) <0.01 
HbA1c, % 4.9 (0.4)§ 6.0 (1.1)|| <0.01 
Treatment of diabetes & car iova cular risk factors    
Diabetes nutritional therapy - 65.9  
Oral antidiabetic drugs - 50.0  
Insulin - 12.4  
Antihypertensive treatment 34.9 50.0 <0.01 
Lipid-lowering treatment 22.1 35.6 <0.01 
Data in tables are percentages for categorical variables and means (SD) for continuous variables.  
* The threshold between moderate and heavy drinking is ≥20 g/day in men and ≥10 g/day in women 
† MEDAS: Mediterranean Diet Adherence Screener (range 0-14)  
‡ Ischemic heart disease, stroke or heart failure 
§4.9% NGSP = 30 mmol/mol IFCC 
||6.0% NGSP= 42 mmol/mol IFCC 
Hs-CRP: High-sensitivity C-reactive protein; HbA1c: Glycated hemoglobin.  
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Table 2: Odds ratios (95% confidence interval) of frailty by socio-demographic factors, health 
behaviors, clinical variables and cardio-metabolic biomarkers. All models are adjusted for sex, age 
and educational level. 
 
 Odds ratio 
 (95% confidence interval) 
Socio-demographic factors  
Sex (women) 2.50 (1.61-3.90) 
Age, years  1.13 (1.10-1.16) 
Educational level  
≤Primary 1.00 (ref)) 
Secondary 0.39 (0.21-0.73) 
University 0.50 (0.28-0.92) 
Health behaviors  
Smoking  
Never 1.00 (ref) 
Former 1.52 (0.86-2.70) 
Current 1.03 (0.41-2.55) 
Alcohol consumption  
Never 1.00 (ref) 
Ex-drinker 0.83 (0.42-1.61) 
Current moderate drinker * 0.53 (0.31-0.91) 
Current heavy drinker * 0.87 (0.44-1.69) 
Time watching TV (hours/day) 1.02 (1.01-1.04) 
Physical activity (MET-hours/week) 0.94 (0.92-0.96) 
MEDAS (continuous) † 0.90 (0.80-0.99) 
Energy intake (per 100 kcal/day) 1.00 (0.96-1.04) 
Abdominal obesity  2.64 (1.61-4.33) 
Morbidity  
Cardiovascular disease‡ 1.57 (0.77-3.17) 
Cancer 1.56 (0.43-5.60) 
Asthma or chronic bronchitis 1.55 (0.81-2.98) 
Osteoarthritis/arthritis 2.09 (1.32-3.32) 
Hip fracture 1.80 (0.54-6.03) 
Cardio-metabolic biomarkers  
Hs-CRP (per mg/dl) 
Model 2 and fibrinogen 
Model 2 and leptin 
Model 2 and systolic blood pressure 
Model 2 and HDL and Triglycerides 
Model 2 and HDL and Triglycerides and LDL 
Model 2 and glycated hemoglobin  
Model 2 and all the above mediators (model 3) 
1.48 (1.23-1.80) 
Fibrinogen (per g/l) 1.23 (0.94-1.61) 
Leptin (per ng/dl, log-transformed) 1.87 (1.38-2.54) 
Systolic blood pressure (per 5 mmHg) 1.01 (0.96-1.06) 
HDL-cholesterol (per 5 m /dl) 0.91 (0.85-0.99) 
Triglycerides (per 5 mg/l) 1.04 (1.02-1.05) 
LDL-cholesterol (p r 5 mg/d ) 0.92 (0.89-0.96) 
HbA1c (per 1 % unit) 1.48 (1.20-1.81) 
Treatment of diabetes and of cardiovascular risk factors  
Diabetes nutritional therapy (among diabetic participants) 0.82 (0.40-1.71) 
Oral antidiabetic drugs (among diabetic participants) 1.59 (0.77-3.29) 
Insulin (among diabetic participants) 1.60 (0.62-4.11) 
  Antihypertensive drugs (among  hypertensive participants) 
 
1.25 (0.79-1.97) 
Lipid-lowering drugs (among  hyperlipidemic participants) 0.93 (0.58-1.48) 
* The threshold between moderate and heavy drinking is ≥20 g/day in men and ≥10 g/day in women  
† MEDAS: Mediterranean Diet Adherence Screener (range 0-14) 
‡ Ischemic heart disease, stroke or heart failure 
Hs-CRP: High-sensitivity C-reactive protein; HBA1c: Glycated hemoglobin.  
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Table 3. Odds ratios (95% confidence interval) of frailty in diabetic versus non-diabetic subjects 
with progressive adjustment for possible mechanism of the association 
 Odds ratio  
(95% confidence 
interval) 
Adjusted for age, sex, and educational level (basic model) 2.18 (1.42-3.37) 
Additionally adjusted for health behaviors and morbidity  
Basic model and lifestyle factors (smoking, alcohol consumption, time 
spent watching TV, recreational activity, MEDAS, energy intake) 
2.01 (1.28-3.16) 
Basic model and abdominal  obesity 1.96 (1.26-3.03) 
Basic model and lifestyle factors and abdominal obesity (model 1) 1.83 (1.16-2.90) 
Additionally adjusted for morbidity  
Model 1 and cardiovascular disease (heart disease, stroke, heart failure), 
cancer, chronic respiratory disease, arthritis, osteoarthritis, fracture 
(model 2) 
1.76 (1.10-2.82) 
Additionally adjusted for cardio-metabolic biomarkers  
Model 2 and HS-CRP 1.71 (1.06-2.76) 
Model 2 and fibrinogen 1.75 (1.09-2.80) 
Model 2 and leptin 1.80 (1.12-2.88) 
Model 2 and systolic blood pressure 1.79 (1.11-2.87) 
Model 2 and HDL-cholesterol 1.64 (1.00-2.69) 
Model 2 and HDL-cholesterol, triglycerides and LDL-cholesterol 1.47 (0.89-2.43) 
Model 2 and HbA1c 1.51 (0.83-2.74) 
Model 2 and all the above mediators (model 3) 1.32 (0.70-2.49) 
Additionally adjusted for treatment of diabetes and of cardiovascular 
risk factors 
 
Model 3 and diabetes nutritional therapy 1.64 (0.77-3.49) 
Model 3 and with oral antidiabetic drugs 1.01 (0.46-2.20) 
Model 3 and insulin 1.29 (0.68-2.45) 
Model 3 and treatment with nutritional therapy, oral antidiabetics and/or 
insulin 
1.28 (0.57-2.91) 
Model 3 and antihypertensive drug treatment 1.35 (0.72-2.55) 
Model 3 and lipid-lowering drug treatment 1.35 (0.72-2.55) 
Model 3 and all the above treatments (model 4) 1.32 (0.58-2.98) 
Analyses were based on 76 frailty cases among 1404 non-diabetic subjects and 39 frailty cases among 346 
diabetic subjects 
Hs-CRP: High-sensitivity C-reactive protein; HBA1c: Glycated hemoglobin.  
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Table 4: Odds ratios (95% confidence interval) of each frailty criterion in diabetic versus non-
diabetic subjects with progressive adjustment for possible mechanism of the association. 
 Odds ratio  
(95% confidence interval) 
  
Exhaustion  
Model 1 0.97 (0.59-1.60) 
Model 2   0.95 (0.58-1.58) 
Model 3  0.99 (0.53-1.85) 
Model 4 0.60 (0.24-1.51) 
  
Low physical activity  
Model 1 0.76 (0.48-1.20) 
Model 2  0.76 (0.48-1.20) 
Model 3 0.69 (0.39-1.20) 
Model 4 0.66 (0.31-1.41) 
  
Slow walking speed  
Model 1 1.49 (1.00-2.23) 
Model 2  1.55 (1.03-2.33) 
Model 3 1.34 (0.81-2.22) 
Model 4 1.43 (0.74-2.76) 
  
Weight loss  
Model 1 1.67 (1.00-2.77) 
Model 2  1.60 (0.95-2.69) 
Model 3 1.27 (0.67-2.44) 
Model 4 1.93 (0.91-4.08) 
  
Weakness  
Model 1 1.17 (0.85-1.61) 
Model 2  1.17 (0.84-1.62) 
Model 3 1.30 (0.87-1.95) 
Model 4 1.33 (0.79-2.25) 
  
Analyses were based on the following cases (events/total in non-diabetic and diabetic individuals: 
Exhaustion (103/1158 and 23/251), low-physical activity (155/1158 and 28/251), slow walking speed 
(125/1150 and 40/249), weight loss (72/1148 and 24/249) and weakness (332/1157 and 87/250). 
Model 1 is adjusted for age, sex, educational level, lifestyle factors and abdominal adiposity; Model 2 is 
further adjusted for self-reported morbidity; Model 3 is further adjusted for cardio-metabolic biomarkers; 
and model 4 is further adjusted for treatment of diabetes and of cardiovascular risk factors. 
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